Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04592822Phase 1Unknown

A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

Role: lead

NCT04591535Phase 1Unknown

PK Study of WD-1603 in Healthy Subjects

Role: lead

NCT04553978Phase 1Unknown

A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions

Role: lead

NCT04513340Phase 1Unknown

WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects

Role: lead

NCT03761004Phase 1Completed

WD-1603 PK Study in Healthy Volunteers

Role: lead

All 5 trials loaded